Envenoming by the Brazilian pit viper, Bothrops jararaca, induces extensive local and systemic haemorrhage in humans. The severe and occasionally lethal outcome of envenoming is prevented only by administration of antivenom which is conventionally prepared by hyperimmunization of large animals with an individual venom or a range of venoms. Since snake venoms typically consist of numerous molecules, only some of which are toxic, antivenoms are antigenically crude preparations whose therapeutic value would theoretically be enhanced by restricting antibody specificity to toxic venom molecules. We report here that high-titre IgG antibody from mice immunized by the GeneGun with DNA encoding the carboxy-terminal JD9 domain of Jararhagin, a haemorrhage-inducing metalloprotease in B. jararaca venom, extensively neutralized the main lethal component of B. jararaca venom. This is to our knowledge the first study to apply DNA-based methods to preparation of antivenom; it represents a novel approach with greater immunological specificity and fewer hazards than conventional systems of antivenom production.
INTRODUCTION
The world-wide mortality from snake bite is estimated at 50 000 deaths annually [1] . The only effective treatment for systemic envenoming is the administration of antivenom. Conventional antivenoms are prepared from sera of large animals, usually horses, hyperimmunized with an individual venom or a range of venoms. Since snake venoms typically consist of numerous molecules, only some of which are toxic, antivenoms therefore include numerous antibodies with specificities not confined to the toxic target molecules. Also, an antivenom production system with less reliance upon snake collection, maintenance and venom extraction to provide material for immunization would reduce the significant hazards and associated costs of conventional procedures. Venom-induced haemorrhagic activity is probably the most important lethal effect of viperine venoms. The present study therefore examined whether a DNA immunization approach targeting part of the major haemorrhagin of Bothrops jararaca venom could be devised to elicit antibodies with greater specificity and equal effectiveness to conventional systems.
The antibody-inductive potency of genetic immunization is often understated in the DNA vaccine literature, where the objectives have generally been to stimulate cellular responses to protect against intracellular pathogens [2] . The markedly T helper 2-type polarized immune response achieved by GeneGun DNA delivery over intramuscular (i.m.) injection of DNA [3, 4] was exploited here to promote antibody induction. A toxin present in the venom of B. jararaca [5] , Jararhagin, was selected to test the concept of DNA-based antivenoms because its cDNA sequence (EMBL accession number X68251) and haemorrhagic activity are well documented [6±8] . Jararhagin represents a group of haemorrhagins common to most viper venoms [9] ; it is a 52-kD soluble zinc-dependent metalloprotease (MP) from which the protein containing the carboxyl-disintegrin and cysteine-rich domain has been isolated (Jararhagin C [10] ) and expressed in Escherichia coli, JD9 [11] . Jararhagin has a structural organization and functional motifs conserved in haemorrhagins of other viper venoms [12, 13] . DNA encoding the JD9 domain, rather than the whole molecule or the MP domain, was used for immunization because expression of JD9 in mammalian cells was considered to pose less host insult than expression of the complete molecule or the MP domain. Also, recent reports suggested to us that antibody bound to JD9 might perturb the catalytic activity and substrate specificity of the intact molecule [13±15].
MATERIALS AND METHODS

Preparation of DNA constructs
The JD9 domain of Jararhagin was polymerase chain reaction (PCR)-amplified from the cDNA sequence using primers complementary to nucleotides 1066±1093 (5 H primer) and nucleotides 1684±1697 (3 H primer). The PCR product was subcloned into a T/A cloning plasmid (PCR2000-TOPO; Invitrogen, Groningen, The Netherlands) and the amplified product ligated into the mammalian DNA expression plasmid, pSecTagB (Invitrogen) and subjected to DNA sequencing to verify that the JD9 DNA sequence was in frame with the coding sequence of the vector. Transformed E. coli colonies were amplified in 500 ml LB cultures and the plasmid DNA constructs purified chromatographically (MegaPrep; Qiagen, Hilden, Germany).
Production of DNA-coated gold beads for GeneGun immunization
The JD9/pSecTagB DNA construct and the control, pSecTagB plasmid were precipitated onto 1´6-m m gold beads and loaded into half-inch lengths of plastic tubing according to the manufacturer's instructions (BioRad, Hercules, CA). The quantity of gold powder and DNA was adjusted to provide pieces of tubing (`shots') containing 1 mg DNA/0´5 mg gold. The abdomens of anaesthetized, 8±10-week-old male BALB/c mice were shaved and each subjected to three`shots' expelled under a burst of helium gas at 350 psi into the epidermal layer using the Helios GeneGun (BioRad). Groups of 10 BALB/c mice were immunized with 3 mg of the JD9 DNA construct or the vector alone, on three occasions, 2 weeks apart and their sera examined 4 weeks later.
Intramuscular injection of DNA JD9/pSecTagB DNA was adjusted to 100 mg DNA/50 ml distilled water and 25 ml injected into each rectus femoris muscle of mice with a 25 G needle on three occasions, 2 weeks apart.
ELISA
Ninety-six-well plates (ICN, Costa Mesa, CA) were coated with Jararhagin (100 ng/well) in 0´05 m carbonate buffer overnight at 48C. The plates were washed with TST (Tris (0´01 m, pH 8´5), saline (NaCl, 0´15 m) and Tween 20 (0´1%)) and blocked for 1 h with 5% fat-free dried milk (Carnation, Wirral, UK) in TST at 378C. Individual sera from immunized animals were diluted 1:500 with 5% milk and applied, in duplicate, to the plates overnight at 48C. The plates were washed with TST and horseradish peroxidase (HRP)-conjugated anti-mouse immunoglobulin reagents (Nordic, Tilburg, The Netherlands), diluted to 1:1000 with TST, were then added for 2 h at 378C. The plates were washed and the assay developed with a 0´02% solution of the chromogenic substrate 2,2 Hazino-bis (2-ethylbenzthiazoline-6-sulphonic acid; Sigma, Poole, UK) in phosphate±citrate buffer (pH 4´0) containing 0´015% hydrogen peroxide and the optical density (OD) was read at 405 nm.
One-dimensional SDS±PAGE Whole B. jararaca venom, fast performance liquid chromatography (FPLC)-purified Jararhagin (1 mg/ml) and recombinant JD9 (100 m g/ml) were solubilized in SDS±PAGE loading buffer (2% SDS, 5% b-mercaptoethanol in 62 mm Tris±HCl, pH 6´8), boiled for 5 min and fractionated on a 12% SDS±PAGE gel.
Two-dimensional isoelectric focusing and SDS±PAGE Whole B. jararaca venom (20 m g) was solubilized in lysis buffer (9´5 m urea, 5% 2-mercaptoethanol, 2% NP40, 2% ampholines; in proportion pH 3´5±10 range). After centrifugation at 16 000 g to remove insoluble material, samples were fractionated by isoelectric focusing (IEF), followed by 8±20% gradient SDS±PAGE.
Immunoblotting
Proteins from the above gels were transferred to nitrocellulose and molecular weight markers visualized by reversible staining with Ponceau S. The filters were blocked with 5% non-fat milk for 1 h at room temperature, washed with TST and diluted (5% milk) sera added overnight at 48C. The filters were washed three times with TST and incubated with HRP-or alkaline phosphatase-conjugated goat anti-mouse IgG, or anti-rabbit IgG (1:1000; Nordic) for 2 h at room temperature. After washing off unbound secondary antibody, the specific antigen-bound antibody was visualized with the appropriate substrate buffer.
Assay to evaluate antibody neutralization of venom-induced haemorrhagic activity Using WHO-approved methods [16, 17] , the Minimum Haemorrhagic Dose (MHDÐthe minimum amount of venom required to produce a haemorrhagic lesion of 35 mm in this study, 24 h after intradermal injection [18] ) of B. jararaca venom was predetermined (24 mg/mouse), adjusted to 100 ml with saline and incubated with sera or saline for 30 min at 378C. The mixture was then injected intradermally into the dorsal skin of anaesthetized outbred mice and 24 h later the inner surface of the skin was examined for evidence of venom-induced haemorrhagic activity. The diameter of each haemorrhagic lesion was measured in two directions, at right angles, using callipers and background illumination and the size of the lesion expressed as a percentage of the 35-mm lesion produced by the MHD.
RESULTS
Mice immunized with JD9/pSectagB DNA by GeneGun or by i.m. injection did not show any obvious adverse local or systemic reaction to the expression of the carboxy terminal disintegrin and cysteine-rich domain of Jararhagin.
Elicitation of high-titre, Jararhagin-specific, IgG antibody by GeneGun immunization of mice with JD9/pSecTagB DNA To determine whether GeneGun DNA immunization raised antigen-specific antibodies of comparable titre to that of animals hyperimmunized with venom components, the end point titres of Jararhagin-specific IgG of sera from mice immunized with the JD9/pSecTagB construct was compared with that of sera from a rabbit (from a previous study) immunized with Jararhagin in Freund's complete adjuvant (FCA) in ELISA (Fig. 1) . The similarly high IgG titres of the murine and rabbit sera (Fig. 1,  lanes 2 and 3, respectively) demonstrate the ability of GeneGun immunization to evoke highly potent antibody responses. In contrast, mice immunized by i.m. injection with JD9/pSecTagB DNA raised only modest IgG antibody titres (Fig. 1, lane 4) that, nevertheless, were significantly higher than background levels determined from control mice immunized with pSecTagB plasmid alone (Fig. 1, lane 1) . Jararhagin-specific IgM, IgA or IgE antibodies were not detected in sera of the DNA immunized mice (data not shown), indicating that the immunoglobulin response to JD9 DNA immunization was restricted to IgG.
Sera from mice immunized by the GeneGun with JD9/ pSectagB construct (Fig. 2, lane 2) showed the same restricted reactivity to a 52-kD band in one-dimensional SDS±PAGE immunoblots of B. jararaca venom as sera from a rabbit (also from a previous study) immunized with FPLC-purified native Jararhagin (Fig. 2, lane 4) , demonstrating the antigen specificity of JD9 GeneGun immunization. As expected, sera from a rabbit hyperimmunized with whole venom exhibited a polyspecific response (Fig. 2, lane 3) . The non-reactivity of sera from mice immunized with the control pSecTagB plasmid (Fig. 2, lane 1) demonstrated that the plasmid was incapable of stimulating antibody to Jararhagin.
Neutralization of venom haemorrhagic activity by antibody from mice immunized with JD9 DNA WHO-approved protocols [16, 17] were used to assess the ability of pooled sera from mice immunized with JD9/pSecTagB or control pSecTagB DNA to neutralize the MHD [18] (24 mg/ mouse) of B. jararaca venom. Preincubation of whole venom with 100 ml of sera from the JD9/pSecTagB DNA-immunized mice reduced the size of the haemorrhagic lesion by 77% (Fig. 3b) . Preincubation of the same amount of venom with 100 ml of rabbit anti-whole B. jararaca venom completely neutralized the MHD (Fig. 3d) . The extent of haemorrhage after preincubation with sera from mice immunized with pSectagB alone (Fig. 3c) was indistinguishable from that obtained by administration of venom preincubated with saline (Fig. 3a) . Prior incubation of venom with normal mouse sera before incubation with the DNA-immunized mouse sera did not affect lesion size (data not shown), indicating that neutralization of haemorrhage was exerted by JD9-specific antibody and not influenced by natural inhibitors (e.g. a 2 -macroglobulin) present in normal sera [19] .
Jararhagin is a dominant component of BX jararaca venom
The extent to which sera from the JD9/pSecTagB DNAimmunized mice neutralized the haemorrhagic activity of B. jararaca venom was somewhat unexpected because Jararhagin is only one of a number of haemorrhage-inducing molecules present in this venom [20] . In an attempt to explain this result, twodimensional SDS±PAGE (2DE) immunoblots of B. jararaca venom were probed with sera from a rabbit hyperimmunized with whole venom or pooled sera from the JD9 DNA-immunized mice (Fig. 4) . The reactivity of the rabbit antivenom confirmed that venom consists of at least 20±25 immunogenic components that differed in their amounts and/or the intensity of immunoreactivity (Fig. 4a) . The dominant 52-kD 2DE elements reactive with the rabbit antivenom were identically, and uniquely, reactive with sera from mice immunized with JD9/pSecTagB DNA (Fig. 4b) , demonstrating them to be Jararhagin isoforms or immunologically cross-reactive molecules. The reason for the`smearing' of these 2DE elements is unclear and could have been due to an artefact of overloading of antigen.
The Jararhagin band immunoreactive with the anti-JD9 mouse sera in the 1DE immunoblots (Fig. 2) was broader than that reactive with rabbit anti-Jararhagin sera. In the light of the 2DE immunoblots, we interpret this as an indication that the rabbit had been immunized with only one isoform of Jararhagin, the others presumably deselected by the pH conditions of FPLC.
DISCUSSION
Conventional antivenoms are prepared by immunization of horses with a single venom or with a range of venoms. Several immunizations with gradually increasing amounts of immunogen are administered to invoke high-titre antibody responses and the IgG fraction of the sera selected for its venom-neutralizing capabilities [21] . The data presented here confirm our original hypothesis that GeneGun immunization with DNA encoding elements of toxic venom molecules is capable of stimulating IgG antibody titres equivalent to that of rabbits hyperimmunized with whole venom. DNA immunization therefore meets the minimal requirements of an antivenom production system. The modest titres observed from mice intramuscularly injected with JD9/ pSecTagB DNA compare unfavourably with titres achieved by GeneGun immunization, as predicted by our own work [22] and others [3, 4] , and ratified the selection of GeneGun over i.m. injection for delivery of DNA for the purposes of this study. More significantly, we have shown that sera from JD9/pSecTagB DNAimmunized mice are capable of neutralizing over 70% of B. jararaca venom-induced haemorrhage, thus demonstrating that antibody raised by GeneGun DNA immunization contains the most important functional capabilities of antivenom, namely neutralization of a toxin responsible for the effects of envenoming. Jararhagin is a member of the metalloproteinase disintegrin cysteine-rich (MDC) family of venom proteins that show a strong structural and functional homology with mammalian matrixdegrading metalloproteinases [13] . MDCs contain two functionally dependent domains: an N-terminal, Zn 21 -containing catalytic domain (MP) with broad substrate specificity (e.g. proteolysis of matrix proteins) [9] that contributes to haemorrhage by lysis of subendothelium, and a disintegrin domain that binds the molecule to a 2 b 1 -integrins on platelets and inhibits platelet interaction with collagen [7±8,23] . The extensive inhibition of this venom-induced haemorrhage by sera restricted to JD9 required explanation because it predicated that the haemorrhagic activity of B. jararaca venom is exerted primarily by Jararhagin (and/or Jararhagin-like MDCs immunologically cross-reactive with JD9) and that the JD9 domain is structurally linked to the MP domain. Figure 4b demonstrated that B. jararaca venom consists of three, perhaps four, molecules reactive with anti-JD9 sera. The immunological specificity and size (52 kD, the molecular weight of native Jararhagin) of these molecules prevented the identification of Jararhagin as distinct from the other two to three molecules reactive with anti-JD9 sera. The latter are likely to represent Jararhagin isoforms, in agreement with previous estimates [23] or other poorly characterized enzymes similar to Jararhagin. Of all the B. jararaca venom components reactive with rabbit antivenom, the Jararhagin and Jararhagin-like molecules reacted with greatest intensity and were uniquely reactive with anti-JD9 sera. Although our data provide no information as to the proteolytic nature of the Jararhagin-like molecules, the 2DE immunoblot results, together with the abilities of the rabbit antivenom and mouse anti-JD9 sera to neutralize venom-induced haemorrhage, suggest that Jararhagin (and perhaps the related molecules) are indeed responsible for most of the haemorrhagic activity of whole B. jararaca venom. The restricted reactivity of the anti-JD9 sera to 52-kD molecules in 1DE and 2DE immunoblots of B. jararaca venom demonstrates that the 28-kD JD9 domain of Jararhagin [11] , or Jararhagin C, is not cleaved from the native molecule in venom. Therefore, binding of the anti-JD9 antibody to the JD9 domain of Jararhagin would be expected to interfere with the interaction of this domain to the a 2 b 1 -integrins on platelets and thereby contribute to neutralization of venom-induced haemorrhage. Alternatively, reports that the disintegrin-cysteine rich domain modulates the substrate specificity of venom MDCs [14] , and possibly their catalytic function [15] , suggest that the anti-JD9 antibody may directly inhibit the enzymatic degradation of subendothelium by the Jararhagin MP domain. It is conceivable that anti-JD9 antibody operates in both modalities to inhibit venom haemorrhagic activity, and experiments are underway to address this issue.
The observation that anti-JD9 sera failed to inhibit completely venom-induced haemorrhagic activity was likely to be due to the function of a haemorrhagin containing component antigenically distinct from JD9. The third (28-kD) molecule intensely reactive with rabbit antivenom but not with anti-JD9 sera (Fig. 4) was one such candidate and possibly represented a distinct short chain metalloprotease. It is also possible that some of the smaller (and less immunoreactive) venom components detected with rabbit antivenom may be RGD-containing disintegrins which, by interfering with cell adhesion, could be enhancing haemorrhage [24] . An earlier report [25] of a monoclonal antibody that neutralized the haemorrhagic activity of the West African carpet viper (Echis ocellatus, formally E. carinatus) supports the present data in demonstrating that the therapeutic effectiveness of antivenom is not necessarily compromised by restricting its antigenic specificity.
In conclusion, we predict that expanding the antigenic specificity of the DNA constructs to include other haemorrhagins in B. jararaca venom will produce sera with even greater potential to neutralize venom-induced haemorrhage. We further predict that the application of immunopotentiators of DNA immunization (e.g. GeneGun co-administration of venom-derived DNA with antibody-enhancing cytokine DNA plasmids, such as murine granulocyte-macrophage colony-stimulating factor (GM-CSF)) will evoke antibody titres higher than those achieved here and with the potential to neutralize completely haemorrhagic activity of viper venoms. Furthermore, we are developing humanized MoAbs from DNA-immunized mice with a view to generating therapeutic sera that pose little risk of serum sickness; a serious clinical consequence of administration of conventional, horsederived antivenoms [21] . The application of DNA-based methodologies to the development of therapeutic antivenom represents the first major conceptual change in antivenom production in over a century and has the potential to provide a more cost-effective, less hazardous and more immunologically specific therapy than those used currently to treat envenoming by snakes.
